TW276181B - - Google Patents

Info

Publication number
TW276181B
TW276181B TW080109698A TW80109698A TW276181B TW 276181 B TW276181 B TW 276181B TW 080109698 A TW080109698 A TW 080109698A TW 80109698 A TW80109698 A TW 80109698A TW 276181 B TW276181 B TW 276181B
Authority
TW
Taiwan
Application number
TW080109698A
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW276181(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of TW276181B publication Critical patent/TW276181B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW080109698A 1990-12-12 1991-12-10 TW276181B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents
GB9126354A GB2251791B (en) 1990-12-12 1991-12-11 Pharmaceutical compositions containing benzenesulphonamides

Publications (1)

Publication Number Publication Date
TW276181B true TW276181B (zh) 1996-05-21

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080109698A TW276181B (zh) 1990-12-12 1991-12-10

Country Status (30)

Country Link
US (6) US5319097A (zh)
EP (1) EP0490648B1 (zh)
JP (1) JP2585495B2 (zh)
KR (2) KR0183027B1 (zh)
CN (2) CN1043405C (zh)
AP (1) AP285A (zh)
AT (1) ATE131048T1 (zh)
AU (1) AU656157B2 (zh)
BE (1) BE1004229A5 (zh)
CA (2) CA2056066C (zh)
CZ (1) CZ283181B6 (zh)
DE (2) DE4140858A1 (zh)
DK (1) DK0490648T3 (zh)
ES (1) ES2079589T3 (zh)
FI (1) FI101193B (zh)
FR (1) FR2670488B1 (zh)
GB (2) GB2280606B (zh)
GR (1) GR3018318T3 (zh)
HK (2) HK81597A (zh)
HU (2) HU213211B (zh)
IE (1) IE75348B1 (zh)
IL (1) IL100091A (zh)
IT (1) IT1256282B (zh)
MX (1) MX9102473A (zh)
MY (1) MY106315A (zh)
NZ (1) NZ240939A (zh)
PH (1) PH30928A (zh)
RU (1) RU2106140C1 (zh)
SK (2) SK279813B6 (zh)
TW (1) TW276181B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (zh) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (zh) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1216058A2 (en) * 1999-09-20 2002-06-26 Alza Corporation Process for lessening polymorphic conversion of a drug
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
DK1413331T3 (da) * 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
CA2453182A1 (en) * 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
EP3168218B1 (en) 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
EP2170825A2 (en) * 2007-07-30 2010-04-07 Auspex Pharmaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
WO2019130334A1 (en) 2017-12-28 2019-07-04 Council Of Scientific & Industrial Research Process for the preparation of zafirlukast and analogs thereof
AU2022276190A1 (en) 2021-05-19 2024-01-18 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)

Also Published As

Publication number Publication date
BE1004229A5 (fr) 1992-10-13
CA2056066A1 (en) 1992-06-13
HK81397A (en) 1997-06-27
SK279813B6 (sk) 1999-04-13
CA2056066C (en) 2002-04-02
AP285A (en) 1993-09-23
JP2585495B2 (ja) 1997-02-26
ITMI913324A1 (it) 1993-06-11
CN1043405C (zh) 1999-05-19
US5993859A (en) 1999-11-30
CN1105705C (zh) 2003-04-16
CS375691A3 (en) 1992-06-17
HU213211B (en) 1997-03-28
AU8899491A (en) 1992-06-18
KR970005014A (ko) 1997-01-29
FI915826A0 (fi) 1991-12-11
CA2319308A1 (en) 1992-06-13
CZ283181B6 (cs) 1998-01-14
US6143775A (en) 2000-11-07
SK279814B6 (sk) 1999-04-13
HU211126A9 (en) 1995-10-30
CN1243827A (zh) 2000-02-09
CN1062291A (zh) 1992-07-01
GB9418154D0 (en) 1994-10-26
KR0183027B1 (ko) 1999-05-01
US5504216A (en) 1996-04-02
GB2251791B (en) 1995-05-17
KR100207802B1 (ko) 1999-07-15
CA2319308C (en) 2001-08-21
GR3018318T3 (en) 1996-03-31
PH30928A (en) 1997-12-23
IE914310A1 (en) 1992-06-17
FR2670488A1 (fr) 1992-06-19
DE69115229D1 (de) 1996-01-18
ATE131048T1 (de) 1995-12-15
US5612367A (en) 1997-03-18
FI101193B1 (fi) 1998-05-15
GB2280606A (en) 1995-02-08
IT1256282B (it) 1995-11-29
EP0490648A1 (en) 1992-06-17
DE4140858A1 (de) 1992-06-17
FI915826A (fi) 1992-03-31
EP0490648B1 (en) 1995-12-06
MX9102473A (es) 1992-06-01
AU656157B2 (en) 1995-01-27
IL100091A0 (en) 1992-08-18
HU913865D0 (en) 1992-02-28
ITMI913324A0 (it) 1991-12-11
IE75348B1 (en) 1997-08-27
DE69115229T2 (de) 1996-05-09
RU2106140C1 (ru) 1998-03-10
DK0490648T3 (da) 1996-05-06
AP9100340A0 (en) 1992-01-31
GB2251791A (en) 1992-07-22
ES2079589T3 (es) 1996-01-16
FR2670488B1 (fr) 1994-01-28
KR920011493A (ko) 1992-07-24
MY106315A (en) 1995-04-29
FI101193B (fi) 1998-05-15
HK81597A (en) 1997-06-27
US5319097A (en) 1994-06-07
JPH04266824A (ja) 1992-09-22
HUT61281A (en) 1992-12-28
IL100091A (en) 1998-08-16
GB2280606B (en) 1995-05-17
GB9126354D0 (en) 1992-02-12
NZ240939A (en) 1994-05-26
US5482963A (en) 1996-01-09

Similar Documents

Publication Publication Date Title
TW276181B (zh)
DE9001666U1 (zh)
DE9003356U1 (zh)
DE9001432U1 (zh)
DE9001709U1 (zh)
DE9002409U1 (zh)
DE9002292U1 (zh)
DE9002100U1 (zh)
DE9003155U1 (zh)
DE4190623T (zh)
DE9001429U1 (zh)
DE9001807U1 (zh)
DE9001065U1 (zh)
DE4190245T (zh)
DE9002541U1 (zh)
DE9003195U1 (zh)
DE9001968U1 (zh)
DE9107618U1 (zh)
DE9007454U1 (zh)
DE9001881U1 (zh)
DE9001047U1 (zh)
DE9002601U1 (zh)
DE9001088U1 (zh)
DE9002581U1 (zh)
DE9001503U1 (zh)

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent